Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC

Video

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy, director of Thoracic Oncology, and professor of oncology, Johns Hopkins Medicine, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer (NSCLC).

While awaiting next-generation sequencing (NGS) results, patients with symptomatic NSCLC should be started on chemotherapy without immunotherapy, says Brahmer. Moreover, patients with adenocarcinoma or a subtype of NSCLC that is associated with a high prevalence of actionable fusions or mutations should wait to begin immunotherapy. Additionally, because BRAF V600E and MET exon 14 skipping mutations are being identified in smokers, as well as never smokers, it is important to wait until NGS results are back to initiate immunotherapy in both patient populations, Brahmer adds.

Conversely, patients with squamous NSCLC who have a low likelihood of harboring an actionable mutation could be started on combination chemotherapy and immunotherapy, concludes Brahmer.

Related Videos
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania